🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Predicting 30-year CV outcomes in women Paul Ridker talks about the Women’s Health Study, which assessed the predictive value of 3 biomarkers - LDL-c, hsCRP, and Lp(a) - in a single blood sample of 1993 in women. Learn more: pace-cme.org/segment/27016/ #ESCCongress #biomarkers #CVD

β-blocker therapy cannot be safely withdrawn in stable post-MI patients Read more: pace-cme.org/news/b-blocker… #ESCCongress #ABYSS #postMI #betablocker #Cardiotwitter

Lessons from global survey on Lp(a) levels in CHD Read more: pace-cme.org/news/lessons-g… #ESCCongress #Lpa #CardioTwitter #CHD #INTERASPIRE

Optimizing care for patients with CKM syndrome: a multidisciplinary approach Learn more: pace-cme.org/programs/cme/o… #CME #CardioTwitter #CKM #Cardiovascular #Kidney #Metabolic

Phase 3 study results of the APOC3 siRNA plozasiran in patients with familial chylomicronemia syndrome Learn more: pace-cme.org/topics/hyperli… #chylomicronemia #plozasiran #FCS #APOC3

Tirzepatide reduces HF events in patients with HFpEF and obesity “This is really very exciting news and information. We think it would change the practice of how these patients are treated in the future”, says Milton Packer Watch: pace-cme.org/congress-cover… #AHA2024 #SUMMIT #HF

Promising results with oral Lp(a) inhibitor in phase 2 trial Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin was investigated in patients with elevated Lp(a) levels and high CV risk. Watch: pace-cme.org/congress-cover… #AHA24

No effect of anticoagulation on cognitive decline in patients with AF at low risk of stroke Read more: pace-cme.org/news/effect-an… #AHA24 #CardioTwitter #AF #Stroke #Cognitivedecline #BRAINAF

DOAC versus VKA after bioprosthetic valve replacement Read more: pace-cme.org/news/doac-vers… #AHA24 #CardioTwitter #Edoxaban #DOAC #VKA #ENBALV

Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH Stephen Nicholls shares the findings of the phase 3 BROOKLYN study. Watch: pace-cme.org/congress-cover… #CETP #lipids #FH #Obicetrapib #HeFH #AHA24 #BROOKLYN #CardioTwitter

Clinical choices in managing LDL-c: Where do novel therapies fit in? Four experts discuss why LDL-c goal attainment is essential. Which options for LDL-c lowering are available, and where do novel therapies fit in? Learn more: pace-cme.org/programs/cme/c… #lipids #CardioTwitter

Icosapent ethyl in post-CABG patients with diabetes Learn more: pace-cme.org/topics/hyperli… #cardiotwitter #icosapentethyl #CABG #diabetes

PACE-CME reports news from the ACC.25 Scientific Session. Follow our news coverage here: pace-cme.org/congress-cover… #ACC25 #cardiology #cardiovascular #diabetes #CVD

Single LDL-c, hs-CRP, and Lp(a) measurement predicts long-term MACE risk in healthy Europeans Read more: pace-cme.org/news/single-ld… #lipids #inflammation #CVD #CardioTwitter #CVrisk

Echo essentials for HCM: The heartbeat of diagnosis and treatment Three HCM experts discuss the role of echocardiography and other imaging techniques in the diagnosis and treatment of HCM Learn more: pace-cme.org/programs/cme/e… #HCM #cardiomyopathy

Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes - great multidisciplinary discussion PACE-CME Henry Han Antonio Cannata' Marco Metra pace-cme.org/programs/cme/s…

Is GLP-1RA use harmful or safe in patients with HFrEF and obesity? Varun Sundaram, MD, PhD, MSc, FRCP (UK) shares the results of the PRAISE-HFrEF study. Watch: pace-cme.org/congress-cover… #HeartFailure2025 #HFrEF #Obesity #PRAISEHFrEF #GLP1RA

Additional follow-up shows vutrisiran reduces mortality and CV event risks in ATTR-CM Read more: pace-cme.org/news/additiona… #HeartFailure2025 #ATTRCM #CardioTwitter

Thanks PACE-CME for covering our #LBCT European Society of Cardiology #HFA from #FINEARTSHF on the impact of randomization during/shortly post HF hosp on early HF readmission rates. Paper simpub in Journal of Cardiac Failure! Dedicated #REDEFINEHF trial underway to validate these findings. pace-cme.org/congress-cover…

🔥🔥🔥 #ESCPrev2025 Satellite symposium on “Novel Therapies for Managing Patients with #CardioKidneyMetabolic syndrome & #HeartFailure” Together with Riccardo M. Inciardi, MD, PhD & Cristina Gavina is now available for your view on PACE-CME Do not miss it! : bit.ly/3GfTT8Q European Society of Cardiology